Genmab A/S - American Depositary Shares (GMAB) closed at $53.63 on November 6, 2026, up 1.7% from the previous close, on volume of 6,411,834 shares (30-day average 5,646,281).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 27, 2026 | Call with Delta Hedge | 20-Nov-26 50 C +210,000 Stock | 10,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Bank of America Securities Sticks to Its Buy Rating for Genmab (GMAB)
TipRanks (Sat, 7-Nov 12:35 AM ET)
Genmab Earnings Call Signals Growth, Pipeline Power and 2027 Potential
TipRanks (Fri, 6-Nov 7:15 PM ET)
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX) and Genmab (GMAB)
TipRanks (Fri, 6-Nov 2:50 PM ET)
Truist Financial Sticks to Its Buy Rating for Genmab (GMAB)
TipRanks (Fri, 6-Nov 9:58 AM ET)
Morgan Stanley Keeps Their Hold Rating on Genmab (GMAB)
TipRanks (Fri, 6-Nov 9:57 AM ET)
Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)
TipRanks (Fri, 6-Nov 2:16 AM ET)
Genmab Reports 22% Revenue Growth as Phase 3 Results Strengthen Oncology Portfolio
TipRanks (Thu, 5-Nov 11:33 AM ET)
Seeking Alpha News (Thu, 5-Nov 11:17 AM ET)
Seeking Alpha News (Wed, 4-Nov 12:27 PM ET)
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Genmab A/S - American Depositary Shares trades on the NASDAQ stock market under the symbol GMAB.
As of November 6, 2026, GMAB stock price climbed to $53.63 with 6,411,834 million shares trading.
GMAB has a beta of 0.99, meaning it tends to be less sensitive to market movements. GMAB has a correlation of 0.08 to the broad based SPY ETF.
GMAB has a market cap of $33.47 billion. This is considered a Large Cap stock.
Last quarter Genmab A/S - American Depositary Shares reported $1 billion in Revenue and $5.51 earnings per share. This fell short of revenue expectation by $-5 billion and exceeded earnings estimates by $5.18.
In the last 3 years, GMAB traded as high as $59.97 and as low as $17.24.
The top ETF exchange traded funds that GMAB belongs to (by Net Assets): IBB, FBT, AVDE, CANC, FTQI.
GMAB has outperformed the market in the last year with a price return of +86.0% while the SPY ETF gained +10.8%. GMAB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +79.8% and +22.5%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
GMAB support price is $51.30 and resistance is $54.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GMAB shares will trade within this expected range on the day.
